Global Parkinson's Disease Drug Market

Parkinson's Disease Drug Market Size, Share, Growth Analysis, By Drug Type(Decarboxylase Inhibitors (Levodopa/Carbidopa), Dopamine Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitors), By Route of Administration(Oral, Injection, Transdermal), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region - Industry Forecast 2025-2032


Report ID: SQSG35I2024 | Region: Global | Published Date: February, 2024
Pages: 165 | Tables: 91 | Figures: 76

Parkinson's Disease Drug Market Insights

Parkinson's Disease Drug Market size was valued at USD 4.61 Billion in 2023 and is poised to grow from USD 5.17 Billion in 2024 to USD 13.43 Billion by 2032, growing at a CAGR of 12.1% during the forecast period (2025-2032).

Parkinson's disease is a neurological condition that primarily affects the areas of the brain that regulate movement, making it challenging to carry out daily tasks. Currently, more than 10 million people in the world are suffering from Parkinson's disease. It is caused by a decline in dopamine production and frequently causes tremors, stiffness, trouble walking, and other symptoms. The increasing prevalence of the disease and the long time period required to control its symptoms are expected to fuel the growth of the Parkinson’s disease drug market over the forecast period. The rise in demand for combination therapies that support neural transplantation, the prolonged action of drugs that continuously stimulate dopaminergic neurons, gene therapy, and government funding initiatives all contribute to the market expansion for Parkinson's disease.

Additionally, the market for Parkinson's disease is positively impacted by the rising population, a better healthcare system, research and development efforts, and higher healthcare costs. Moreover, the Parkinson's disease market players are expected to benefit from lucrative prospects throughout the projected period due to the patent expiration of branded pharmaceuticals and a robust drug pipeline.

US Parkinson's Disease Drug Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Parkinson's Disease Drug Market size was valued at USD 4.28 billion in 2019 and is poised to grow from USD 4.61 billion in 2023 to USD 11.98 billion by 2031, growing at a CAGR of 12.1% in the forecast period (2024-2031).

The market for medications for Parkinson's disease is getting increasingly competitive. The market is becoming more active as a result of recent product launches and the large number of medicines in the product pipelines of multinational pharmaceutical companies. A number of new products are expected to be released, which could significantly alter the market shares of pharmaceutical companies that are currently engaged in the market, over the forecast period. 'AbbVie Inc.', 'Acorda Therapeutics Inc.', 'Adamas Pharmaceuticals Inc.', 'Biogen Inc.', 'Britannia Pharmaceuticals Ltd.', 'Denali Therapeutics Inc.', 'F. Hoffmann-La Roche Ltd.', 'GlaxoSmithKline plc', 'H. Lundbeck A/S', 'Impax Laboratories Inc.', 'Intec Pharma Ltd.', 'Ipsen S.A.', 'Kyowa Hakko Kirin Co. Ltd.', 'Merck & Co. Inc.', 'Neurocrine Biosciences Inc.', 'Novartis International AG', 'Pfizer Inc.', 'Teva Pharmaceutical Industries Ltd.', 'UCB S.A.', 'Zambon S.p.A.'

The increasing aging population and the rising number of Parkinson's cases: Rising aging populations and increased prevalence of neurological illnesses are two important factors driving the growth of this market. With the increase in the number of patients with Parkinson’s disease, the demand for the drugs required for the treatment of this disease, is also increasing rapidly. This is expected to support the growth of the parkinson’s disease drug market globally, over the forecast period.

Increasing research and development for treatment of Parkinson’s disease: A key trend in the market for Parkinson's treatments is the rise in government and corporate funding for research and development of Parkinson's disease medications. Companies involved in the drug development for this disease are working towards developing new and innovative drugs for the treatment of the disease. Therefore, the market for Parkinson’s disease drugs is expected to be supported by rising investments in the development of Parkinson's drugs.

Based on the region, the European region currently dominates the Parkinson's disease drug market with respect to market share. Due to the rising prevalence of Parkinson's disease and active government assistance through government-assisted pharmacies, Europe commands the worldwide Parkinson's disease market. However, North America is predicted to hold the largest market share for Parkinson's disease medications due to increased research & development spending and the anticipated approval and launch of new pipeline drug candidates, over the forecast period.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Parkinson's Disease Drug Market

Report ID: SQSG35I2024

$5,300
BUY NOW GET FREE SAMPLE